Cordis Unveils Comprehensive Interventional Cardiology Portfolio With Coronary Stents

October 30, 2017­–Cordis, a Cardinal Health Company announced the addition of two new coronary stents to its comprehensive interventional cardiology portfolio, the Tryton side branch stent and Medinol’s NIRxcell cobalt-chromium bare-metal stent (BMS), during the TCT 2017, the 29th annual Transcatheter Cardiovascular Therapeutics scientific symposium held October 30 to November 2 in Denver, Colorado.

The Tryton side branch stent is approved for the treatment of de novo coronary bifurcation lesions involving large side branches (appropriate for a ≥ 2.5 mm stent), advised the company. Cordis, Cardinal Health’s interventional vascular business, is the exclusive distributor of the Tryton side branch stent in the United States.

According to Cordis, the recent Cardinal Health agreement with Medinol provides them with the exclusive rights to sell Medinol’s coronary stent portfolio in the United States, which includes the NIRxcell BMS. In addition, upon Medinol receiving U.S. Food and Drug Administration approval, Cordis will also be the exclusive distributor of the EluNIR drug-eluting stent (DES).

The EluNIR DES is currently an investigational device and not approved for commercial use in the United States. It has received CE Mark approval in Europe.

Peter Van Haur, Cordis’ Vice President of North America Sales and Marketing, said in the company’s announcement, “The new Medinol agreement, along with the recent launch of the Tryton side branch stent and two Meril PTCA balloon dilatation catheters, reestablishes Cordis in the United States market with a significant interventional cardiology portfolio."